BioAtla Inc
BCAB
Company Profile
Business description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Contact
11085 Torreyana Road
San DiegoCA92121
USAT: +1 858 558-0708
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
61
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,924.20 | 83.70 | 0.95% |
| CAC 40 | 8,057.36 | 142.00 | 1.79% |
| DAX 40 | 23,829.75 | 420.38 | 1.80% |
| Dow JONES (US) | 48,076.11 | 335.31 | 0.70% |
| FTSE 100 | 10,376.35 | 126.83 | 1.24% |
| HKSE | 25,959.90 | 202.61 | 0.79% |
| NASDAQ | 22,837.72 | 141.78 | 0.62% |
| Nikkei 225 | 54,248.39 | 1,372.45 | -2.47% |
| NZX 50 Index | 13,094.37 | 523.52 | -3.84% |
| S&P 500 | 6,826.71 | 30.72 | 0.45% |
| S&P/ASX 200 | 8,692.60 | 90.30 | 1.05% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |